San Francisco, 02 December 2025: The Report Electronic Drug Delivery Devices Market (2025 - 2030) Size, Share & Trends Analysis Report By Product (Implantable Drug Delivery Devices, Smart Metered Dose Inhalers), By Application (Diabetes, Oncology), By Region, And Segment Forecasts
The global electronic drug delivery devices market size is anticipated to reach USD 99.5 billion by 2030 and is anticipated to grow at a CAGR of 8.14% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth can be attributed to the increasing the growing geriatric population and prevalence of chronic diseases, increasing awareness for personalized medicine, rising preference for home healthcare, and the integration of digital technologies. For instance, in June 2024, AptarGroup, Inc. collaborated with SHL Medical to integrate Aptar Digital Health’s SaMD platform with SHL Medical’s advanced drug delivery systems, such as autoinjectors, pen injectors, and specialty delivery systems.
As patients are increasingly preferring to manage their health conditions at home, there is a growing demand for drug delivery devices that enable safe, effective, and easy at-home treatments. Devices such as insulin pumps, auto-injectors, wearable infusion pumps, and pre-filled syringes are becoming indispensable tools in home healthcare because they allow patients to self-administer medications with minimal assistance, offering both convenience and autonomy. For instance, in October 2023, Victrex plc, known for its innovative PEEK biomaterial solutions, introduced an advanced product, the VICTREX PC101 grade, specifically designed for drug delivery and pharmaceutical contact applications. This launch aligns with the growing trend of utilizing drug delivery devices in homecare environments, enhancing accessibility for patients seeking innovative solutions.
Moreover, technology trends in the electronic drug delivery devices market are rapidly advancing, driven by the need for greater precision, personalization, and patient convenience. Some of the new trends include the integration of digital health technologies, wearable drug delivery devices, and the use of microfluidics. The rise of precision medicine is also driving innovation. The devices are being tailored to the individual’s genetic makeup, condition, or specific therapeutic needs, ensuring better outcomes and fewer side effects.
The increasing prevalence of chronic diseases and growing geriatric population, rising preference for home healthcare, increasing awareness of personalized medicine, and the integration of digital technologies are the factors affecting the market's growth. For instance, in September 2024, SHL Medical launched Elexy, a reusable electromechanical drug delivery device designed to support digital therapeutics and a wide array of specialty formulations. This device offers cellular and Bluetooth connectivity options, which facilitate the collection of comprehensive data related to the drug, its container, and the device itself use.
The growing prevalence of chronic diseases is significantly contributing to the growth of the drug delivery devices market. Chronic diseases such as diabetes, cancer, cardiovascular diseases, and respiratory disorders require long-term management, frequently involving daily or regular drug administration to manage symptoms, prevent complications, and improve quality of life. Some of the devices that can be used for this include insulin pumps, inhalers, patches, implantable devices, and continuous glucose monitors.
Request sample report of Electronic Drug Delivery Devices Market@ https://www.grandviewresearch.com/industry-analysis/electronic-drug-delivery-devices-market-report/request/rs1
As per a report by the World Health Organization (WHO), cardiovascular diseases (CVD) are the leading cause of death globally and take an estimated 17.9 million lives each year. Some of the cardiovascular diseases include coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other conditions. Furthermore, according to the WHO, by 2050, the number of new cancer cases is projected to rise by over 35 million.
The rising preference for home healthcare is a significant driver of growth in the electronic drug delivery devices market, as more patients and healthcare systems seek to shift care from hospitals and clinics to home settings. Home healthcare offers patients comfort, privacy, and the convenience of receiving treatment in a familiar environment while reducing the strain on healthcare facilities. This shift is driven by several factors, such as lowering healthcare costs, improving patient outcomes, and increasing access to care.
As patients increasingly prefer to manage their health conditions at home, there is a growing demand for electronic drug delivery devices that enable safe, effective, and easy at-home treatments. Devices such as insulin pumps, auto-injectors, wearable infusion pumps, and pre-filled syringes are becoming indispensable tools in home healthcare because they allow patients to self-administer medications with minimal assistance, offering convenience and autonomy. For instance, in October 2023, Victrex plc, known for its innovative PEEK biomaterial solutions, introduced an advanced product, the VICTREX PC101 grade, specifically designed for drug delivery and pharmaceutical contact applications. This launch aligns with the growing trend of utilizing drug delivery devices in homecare environments, enhancing accessibility for patients seeking innovative solutions.
Furthermore, integrating digital technologies has played a crucial role in transforming drug delivery and improving its precision and safety. Incorporating digital health technologies (DHTs) offers several advantages in developing drug delivery devices. These advancements include electronic sensors, computing platforms, and information technology, all providing new opportunities for collecting clinical trial data directly from patients.
These technologies also include smart drug delivery devices connected to mobile apps, cloud platforms, and digital monitoring systems, enabling real-time tracking and management of medical administration. This digital integration enhances treatment efficiency, improves patient adherence, and allows healthcare providers to monitor patients remotely, reducing the need for in-person visits. For instance, in October 2022, the NEMERA Group, a design, development, and manufacturing company for drug delivery device solutions, partnered with Zollner Elektronik AG, an electronic manufacturing service provider. With this partnership, Zollner will support the design, development, and manufacturing of electronic drug delivery devices for Nemera’s proprietary and customer-owned products, beginning with Nemera’s Symbioze wearable injection device.
